Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma

Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Kim D-W, Mehra R, Tan DSW et al (2016) Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 17(4):452–463

Soria J-C, Tan DSW, Chiari R et al (2017) First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet 389(10072):917–929

Facchinetti F, Gnetti L, Balestra V et al (2019) Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib. Invest New Drugs 37(2):360–363

Shaw AT, Friboulet L, Leshchiner I et al (2016) Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 374(1):54–61

Yoda S, Lin JJ, Lawrence MS et al (2018) Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov 8(6):714–729

Helming L, Gordon S (2009) Molecular mediators of macrophage fusion. Trends Cell Biol 19(10):514–522

Dodiuk-Gad RP, Shear NH (2015) Granulomatous Drug Eruptions. Dermatol Clin 33(3):525–539

Morris DG, Jasmer RM, Huang L et al (2003) Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest 124:929–935

Miranda EJ, Leite OH, Duarte MI (2011) Immune reconstitution inflammatory syndrome associated with pulmonary sarcoidosis in an HIV-infected patient: an immunohistochemical study. Braz J Infect Dis 15:601–606

Foulon G, Wislez M, Naccache JM et al (2004) Sarcoidosis in HIV-infected patients in the era of highly active antiretroviral therapy. Clin Infect Dis 38:418–425

Koda K, Toyoshima M, Nozue T et al (2020) Systemic sarcoidosis associated with certolizumab pegol treatment for rheumatoid arthritis: a case report and review of the literature. Intern Med 59:2015–2021

Ramos-Casals M, Mana J, Nardi N et al (2005) Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine 84:69–80

Friboulet L, Li N, Katayama R et al (2014) The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4(6):662–673

Shaw AT, Kim DW, Mehra R et al (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370(13):1189–1197

Li S, Qi X, Huang Y et al (2015) Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer. Clin Lung Cancer 16(2):86–91

Gainor JF, Tan DS, De Pas T et al (2015) Progression Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res 21(12):2745–2752

Scagliotti G, Kim TM, Crinò L et al (2016) Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)- rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study. Ann Oncol 27(suppl 6):1–36

Shaw AT, Kim TM, Crinò L et al (2017) Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18(7):874–886. https://doi.org/10.1016/S1470-2045(17)30339-X

Crino L, Ahn MJ, De Marinis F et al (2016) Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 34(24):2866–2873. https://doi.org/10.1200/JCO.2015.65.5936

Pellegrino B, Facchinetti F, Bordi P et al (2018) Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature. Clin Lung Cancer 19(2):e151–e161

Novartis Europharm Limited (2015) Zykadia hard capsules: EU summary of product characteristics. http://www.ema.europa.eu. Accessed 19 Sep 2016.

Califano R, Greystoke A, Lal R et al (2017) Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. Lung Cancer 111:51–58. https://doi.org/10.1016/j.lungcan.2017.06.004